This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Cephalon (UK) Limited

Teva UK Limited, Field House, Station Approach, Harlow, Essex, CM20 2FB
Telephone: +44 (0) 207 5407117
Fax: +44 (0) 207 4507349
WWW: http://www.tevauk.com
Medical Information Direct Line: +44 (0) 207 5407117
Medical Information e-mail: medinfo@tevauk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 21/03/2011
SPC Zacin Cream 0.025%


Go to top of the page
1. Name of the medicinal product

Zacin 0.025% w/w Cream


Go to top of the page
2. Qualitative and quantitative composition

Capsaicin 0.025% w/w


Go to top of the page
3. Pharmaceutical form

Cream for topical application


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

For the symptomatic relief of pain associated with osteoarthritis.


Go to top of the page
4.2 Posology and method of administration

Adults and the elderly:

For topical administration to unbroken skin. Apply only a small amount of cream (pea size) to affected area 4 times daily. These applications should be evenly spaced throughout the waking hours and not more often than every 4 hours. The cream should be gently rubbed in, there should be no residue left on the surface. Hands should be washed immediately after application of Zacin unless hands and fingers are being treated. Zacin should not be applied near the eyes. Pain relief usually begins within the first week of treatment and increases with continuing regular application for the next two to eight weeks.

Not suitable for use in children.


Go to top of the page
4.3 Contraindications

Zacin cream is contra-indicated on broken or irritated skin.

Zacin Cream is contra-indicated in patients with known hypersensitivity to capsaicin or any of the excipients used in this product.


Go to top of the page
4.4 Special warnings and precautions for use

Skin irritation has been reported following application of Zacin. The hands should be washed immediately after application of the cream, unless the hands are the treated areas, in which case, they should be washed 30 minutes after application

Patients should avoid taking a hot bath or shower just before or after applying Zacin, as it can enhance the burning sensation.

Patients and carers should avoid inhalation of vapours from the cream, as transient irritation of the mucous membranes of the eyes and respiratory tract (including exacerbation of asthma) has been reported.

Keep Zacin away from the eyes.

Medical advice should be sought if the condition worsens, or clears up then recurs.

Tight bandages should not be applied on top of Zacin cream.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Not applicable.


Go to top of the page
4.6 Pregnancy and lactation

The safety of Zacin during pregnancy and lactation has not been established, in either humans or animals. However, in the small amounts absorbed transdermally from Zacin Cream, it is considered unlikely that capsaicin will cause any adverse effects in humans.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

Zacin may cause skin irritation or transient burning on application. This burning is observed more frequently when application schedules of less than 4 times daily are utilised. The burning can be enhanced if too much cream is used and if it is applied just before or after a bath or shower.

Irritation of the mucous membranes of the eyes and respiratory tract (such as nasal and throat irritation) on application of Zacin cream has been reported rarely, resulting in symptoms such as coughing, sneezing and runny eyes. These events are usually mild and self-limiting. There have been a few reports of dyspnoea, wheezing and exacerbation of asthma.


Go to top of the page
4.9 Overdose

Not applicable.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Topical products for joint and muscular pain, Capsaicin and similar agents, ATC code: M02A B01.

Although the precise mechanism of action of capsaicin is not fully understood, current evidence suggests that capsaicin exerts an analgesic effect by depleting and preventing reaccumulation of Substance P in peripheral sensory neurons. Substance P is thought to be the principal chemomediator of pain impulses from the periphery to the central nervous system.


Go to top of the page
5.2 Pharmacokinetic properties

Absorption after topical application is unknown. Average consumption of dietary spice from capsicum fruit has been estimated at 2.5g/person/day in India and 5.0g/person/day in Thailand. Capsaicin content in capsicum fruit is approximately 1% therefore dietary intake of capsaicin may range from 0.5-1mg/kg/day for a 50kg person. Application of two tubes of Zacin Cream 0.025% (90g) each week results in 3.21mg/day topical exposure. Assuming 100% absorption in a 50kg person, daily exposure would be 0.064mg/kg which is approximately one seventh to one eighth of the above mentioned dietary intake.


Go to top of the page
5.3 Preclinical safety data

The available animal toxicity data relating to capsicum, capsicum extracts and capsaicin do not suggest that, in usual doses, they pose any significant toxicity hazard to man. Thus, in both single and repeat dosing studies which have been reported, capsicum extracts and capsicum are generally well-tolerated at many times even the highest estimated human intakes. The safety of Zacin for use in human pregnancy has not been established since no formal reproduction studies have been performed in either animals or man. However, there is no reason to suspect from human or animal studies currently available that any adverse effects in humans are likely.

Studies reported in the published literature which relate to potential genotoxic and carcinogenic action of capsaicin have produced inconclusive and conflicting data. However, it is unlikely that capsaicin, in the quantities absorbed transdermally from Zacin cream, will pose any significant hazard to humans.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Purified Water

Sorbitol Solution

Isopropyl Myristate

Cetyl Alcohol

White Soft Paraffin

Glyceryl Stearate and Peg-100

Stearate (Arlacel 165)

Benzyl Alcohol


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

3 years


Go to top of the page
6.4 Special precautions for storage

Store below 25°C.

Return any unused cream to your doctor or pharmacist.


Go to top of the page
6.5 Nature and contents of container

Aluminium tubes with epoxyphenolic lining and polypropylene spiked cap containing 45g of Zacin Cream 0.025%.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
7. Marketing authorisation holder

Cephalon UK Limited

1 Albany Place

Hyde Way

Welwyn Garden City

Hertfordshire

AL7 3BT


Go to top of the page
8. Marketing authorisation number(s)

PL 16260/0028


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

22 March 2010


Go to top of the page
10. Date of revision of the text

08 March 2011


Go to top of the page
11. Legal category

POM



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/269/SPC/


Active Ingredients/Generics